Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 2, 2013, Pages 139-155

  Wallace, Tanya L ^a   Bertrand, Daniel ^b  

^a SRI INTERNATIONAL   (United States)

^b HiQScreen   (Switzerland)

Author keywords

Alpha7; Nicotinic acetylcholine receptors; Novel drug target; Review; Schizophrenia

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; A 582941; ABT 107; ABT 126; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR AGONIST; CHIBA 1001; CHLORPROMAZINE; CP 810123; DIZOCILPINE; EVP 6124; HALOPERIDOL; JNJ 39393406; MEM 3454; NEUROLEPTIC AGENT; NS 1738; PHA 568487; PLACEBO; PNU 120596; RG 3487; SEN 12333; TC 5619; TROPISETRON; UNCLASSIFIED DRUG; WAY 317538;

COGNITION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA;

EID: 84872234860     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.736498     Document Type: Review

References (171)

1. Davidson M, Reichenberg A Rabinowitz J, et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999;156:1328-35 (Pubitemid 29416527)
2. Cornblatt BA, Lenzenweger MF Dworkin RH, Erlenmeyer-Kimling L. Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. Br J Psychiatry Suppl 1992(18):59-64
3. Mednick SA, Parnas J, Schulsinger F. The Copenhagen high-risk project 1962 - 86. Schizophr Bull 1987;13:485-95
4. Nuechterlein KH. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J Abnorm Psychol 1983;92:4-28
5. Palmer BW, Heaton RK, Paulsen JS et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997;11:437-46 (Pubitemid 27294667)
6. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr Bull 2000;26:119-36 (Pubitemid 30317696)
7. Picchioni MM, Murray RM. Schizophrenia. BMJ 2007;335:91-5 (Pubitemid 47123289)
8. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-92 (Pubitemid 37494071)
9. Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011;43:969-76
10. Sullivan PF. Puzzling over schizophrenia: Schizophrenia as a pathway disease. Nat Med 2012;18:210-11
11. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: The emerging picture and its implications. Nat Rev Genet 2012;13(8):537-51
12. Lederbogen F, Kirsch P, Haddad L, et al. City living and urban upbringing affect neural social stress processing in humans. Nature 2011;474:498-501
13. Tost H, Meyer-Lindenberg A. Puzzling over schizophrenia: Schizophrenia, social environment and the brain. Nat Med 2012;18:211-13
14. Ban TA. Fifty years chlorpromazine: A historical perspective. Neuropsychiatr Dis Treat 2007;3:495-500 (Pubitemid 350028014)
15. Levine JB, Martin G, Wilson A Treistman SN. Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner. Neurosci Lett 2003;346:125-8 (Pubitemid 36829277)
16. Yokota K, Tatebayashi H, Matsuo T et al. The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: Differences between some neuroleptics. Br J Pharmacol 2002;135:1547-55 (Pubitemid 34270927)
17. Abbott A. Schizophrenia: The drug deadlock. Nature 2010;468:158-9
18. Wallace TL, Porter RHP. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011;82:891-903
19. Evans DE, Drobes DJ. Nicotine self-medication of cognitive-attentional processing. Addict Biol 2009;14:32-42
20. Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry 2010;23:112-19
21. Brunzell DH, McIntosh JM. Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 2011;37:1134-43
22. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008;83:531-41 (Pubitemid 351417076)
23. Benowitz NL. Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71
24. Rose JE, Mukhin AG, Lokitz SJ, et al. Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. Proc Natl Acad Sci USA 2010;107:5190-5
25. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007;47:699-729
26. Albuquerque EX, Pereira EFR Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89:73-120
27. Lukas RJ, Changeux JP, Le Novere N et al. International union of pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999;51:397-401 (Pubitemid 29269984)
28. Galzi JL, Bertrand D, Devillers-Thiery A et al. Functional significance of aromatic amino acids from three peptide loops of the alpha 7 neuronal nicotinic receptor site investigated by site-directed mutagenesis. FEBS Lett 1991;294:198-202
29. Corringer PJ, Bertrand S, Bohler S, et al. Critical elements determining diversity in agonist binding and desensitization of neuronal nicotinic acetylcholine receptors. J Neurosci 1998;18:648-57 (Pubitemid 28041901)
30. Brams M, Pandya A, Kuzmin D, et al. A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors. PLoS Biol 2011;9:e1001034
31. Billen B, Spurny R, Brams M, et al. Molecular actions of smoking cessation drugs at alpha4beta2 nicotinic receptors defined in crystal structures of a homologous binding protein. Proc Natl Acad Sci USA 2012;109(23):9173-8
32. Celie PHN, van Rossum-Fikkert SE van Dijk WJ, et al. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004;41:907-14 (Pubitemid 38429734)
33. Palma E, Bertrand S, Binzoni T Bertrand D. Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol 1996;491(Pt 1):151-61
34. Couturier S, Bertrand D, Matter JM et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 1990;5:847-56
35. Seguela P, Wadiche J, Dineley-Miller K et al. Molecular cloning, functional properties, and distribution of rat brain alpha 7: A nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13:596-604 (Pubitemid 23045143)
36. Agulhon C, Abitbol M, Bertrand D Malafosse A. Localization of mRNA for CHRNA7 in human fetal brain. Neuroreport 1999;10:2223-7 (Pubitemid 29367913)
37. Herber DL, Severance EG, Cuevas J et al. Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem 2004;52:1367-76
38. Jones IW, Wonnacott S. Why doesn't nicotinic ACh receptor immunoreactivity knock out? Trends Neurosci 2005;28:343-5 (Pubitemid 40853855)
39. Han Z-Y, Zoli M, Cardona A, et al. Localization of [3H]nicotine, [3H] cytisine, [3H]epibatidine, and [125I] alpha-bungarotoxin binding sites in the brain of macaca mulatta. J Comp Neurol 2003;461:49-60 (Pubitemid 36578596)
40. Tribollet E, Bertrand D, Marguerat A Raggenbass M. Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: An autoradiographic study in the rat brain. Neuroscience 2004;124:405-20 (Pubitemid 38229660)
41. Court JA, Martin-Ruiz C, Graham A Perry E. Nicotinic receptors in human brain: Topography and pathology. J Chem Neuroanat 2000;20:281-98 (Pubitemid 32162887)
42. Gotti C, Clementi F, Fornari A, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009;78(7):703-11
43. Rueter LE, Donnelly-Roberts DL Curzon P, et al. A-85380: A pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor. CNS Drug Rev 2006;12:100-12 (Pubitemid 44313714)
44. Fabian-Fine R, Skehel P, Errington ML et al. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 2001;21:7993-8003 (Pubitemid 32952756)
45. Jones IW, Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 2004;24:11244-52 (Pubitemid 39658259)
46. Dickinson JA, Kew JN, Wonnacott S. Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 2008;74:348-59
47. Descarries L, Gisiger V, Steriade M. Diffuse transmission by acetylcholine in the CNS. Prog Neurobiol 1997;53:603-25 (Pubitemid 27489823)
48. Gu Z, Yakel JL. Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 2011;71:155-65
49. Lagostena L, Trocme-Thibierge C Morain P, Cherubini E. The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 2008;54:676-85
50. Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol 2012;22:496-508
51. Muller-Dahlhaus F, Ziemann U Classen J. Plasticity resembling spike-timing dependent synaptic plasticity: The evidence in human cortex. Front Synaptic Neurosci 2010;2:34
52. Zorumski CF, Izumi Y. NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders. Neurosci Biobehav Rev 2012;36:989-1000
53. Luby ED, Cohen BD, Rosenbaum G et al. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959;81:363-9
54. Malhotra AK, Pinals DA, Adler CM et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997;17:141-50 (Pubitemid 27365955)
55. Verhoog MB, Mansvelder HD. Presynaptic ionotropic receptors controlling and modulating the rules for spike timing-dependent plasticity. Neural Plast 2011;2011:870763
56. Fisher JL, Dani JA. Nicotinic receptors on hippocampal cultures can increase synaptic glutamate currents while decreasing the NMDA-receptor component. Neuropharmacology 2000;39:2756-69
57. Shen H, Kihara T, Hongo H, et al. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol 2010;161:127-39
58. Adams CE, Yonchek JC, Zheng L, et al. Altered hippocampal circuit function in C3H alpha7 null mutant heterozygous mice. Brain Res 2008;1194:138-45
59. Adams CE, Yonchek JC, Schulz KM et al. Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases. Neuroscience 2012;207:274-82
60. Stevens KE, Kem WR, Mahnir VM Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 1998;136:320-7 (Pubitemid 28189660)
61. Andrieux A, Salin PA, Vernet M, et al. The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev 2002;16:2350-64 (Pubitemid 35034405)
62. Biton B, Bergis OE, Galli F, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007;32:1-16 (Pubitemid 44967780)
63. Bodnar AL, Cortes-Burgos LA Cook KK, et al. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem 2005;48:905-8 (Pubitemid 40270435)
64. Hunter BE, de Fiebre CM, Papke RL et al. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci Lett 1994;168:130-4
65. Wallace TL, Chiu G, Dao H, et al. Modulation of Cholinergic Tone Impacts the Efficacy of RG3487/ MEM3454 A Novel, Nicotinic Alpha 7 Receptor Agonist. Society for Neuroscience Meeting; 2010. p. 236.1
66. Castner SA, Smagin GN, Piser TM et al. Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors. Biol Psychiatry 2011;69:12-18
67. Prickaerts J, van Goethem NP Chesworth R, et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2011;62:1099-110
68. Arendash GW, Sengstock GJ Sanberg PR, Kem WR. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 1995;674:252-9
69. Feuerbach D, Lingenhoehl K, Olpe HR et al. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 2009;56:254-63
70. Wallace TL, Callahan PM, Tehim A et al. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 2010;336:242-253
71. Hajos M, Hurst RS, Hoffmann WE et al. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo [2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 2005;312:1213-22 (Pubitemid 40293783)
72. Tietje KR, Anderson DJ, Bitner RS et al. Preclinical characterization of A-582941: A novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther 2008;14:65-82
73. Roncarati R, Scali C, Comery TA, et al. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 2009;329:459-68
74. Pichat P, Bergis OE, Terranova J-P et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007;32:17-34 (Pubitemid 44967781)
75. Hashimoto K, Nishiyama S, Ohba H et al. [11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: A PET study in conscious monkeys. PLoS One 2008;3:e3231
76. Hashimoto K, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: Role of alpha7 nicotinic receptors. Eur J Pharmacol 2006;553:191-5 (Pubitemid 44779614)
77. Leonard S, Freedman R. Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry 2006;60:115-22 (Pubitemid 44026594)
78. Hurst RS, Hajos M, Raggenbass M et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 2005;25:4396-405 (Pubitemid 40628784)
79. Thomsen MS, El-Sayed M Mikkelsen JD. Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One 2011;6:e27014
80. Leiser SC, Bowlby MR, Comery TA Dunlop J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 2009;122:302-11
81. Churchland MM, Cunningham JP Kaufman MT, et al. Neural population dynamics during reaching. Nature 2012;487:51-6
82. Mathewson KE, Gratton G, Fabiani M et al. To see or not to see: Prestimulus alpha phase predicts visual awareness. J Neurosci 2009;29:2725-32
83. Rutishauser U, Ross IB, Mamelak AN Schuman EM. Human memory strength is predicted by theta-frequency phaselocking of single neurons. Nature 2010;464:903-7
84. Moran LV, Hong LE. High vs low frequency neural oscillations in schizophrenia. Schizophr Bull 2011;37:659-63
85. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci USA 2006;103:19878-83 (Pubitemid 46037524)
86. Steriade M. Grouping of brain rhythms in corticothalamic systems. Neuroscience 2006;137:1087-106 (Pubitemid 43133136)
87. Steriade M, Datta S, Pare D, et al. Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci 1990;10:2541-59
88. Lu CB, Henderson Z. Nicotine induction of theta frequency oscillations in rodent hippocampus in vitro. Neuroscience 2010;166:84-93
89. Siok CJ, Rogers JA, Kocsis B, Hajos M. Activation of alpha7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation. Eur J Neurosci 2006;23:570-4
90. Song C, Murray TA, Kimura R, et al. Role of alpha7-nicotinic acetylcholine receptors in tetanic stimulation-induced gamma oscillations in rat hippocampal slices. Neuropharmacology 2005;48:869-80 (Pubitemid 40489042)
91. Flomen RH, Shaikh M, Walshe M, et al. Association between the 2-bp deletion polymorphism in the duplicated version of the alpha7 nicotinic receptor gene and P50 sensory gating. Eur J Hum Genet 2012; Epub ahead of print
92. Martin LF, Leonard S, Hall M-H, et al. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 2007;144B:611-14 (Pubitemid 47077144)
93. Araud T, Graw S, Berger R, et al. The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of alpha7. nAChR function. Biochem Pharmacol 2011;82:904-14
94. de Lucas-Cerrillo AM, Maldifassi MC Arnalich F, et al. Function of partially duplicated human alpha77 nicotinic receptor subunit CHRFAM7A gene: Potential implications for the cholinergic anti-inflammatory response. J Biol Chem 2011;286:594-606
95. Araud T, Wonnacott S, Bertrand D. Associated proteins: The universal toolbox controlling ligand gated ion channel function. Biochem Pharmacol 2010;80:160-9
96. Chimienti F, Hogg RC, Plantard L et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet 2003;12:3017-24 (Pubitemid 37442029)
97. Higley MJ, Strittmatter SM. Neuroscience. Lynx for braking plasticity. Science 2010;330:1189-90
98. Morishita H, Miwa JM, Heintz N Hensch TK. Lynx1, a cholinergic brake limits plasticity in adult visual cortex. Science 2010;330:1238-40
99. Miwa JM, Freedman R, Lester HA. Neural systems governed by nicotinic acetylcholine receptors: Emerging hypotheses. Neuron 2011;70:20-33
100. Chini B, Raimond E, Elgoyhen AB et al. Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics 1994;19:379-81 (Pubitemid 24059335)
101. Gault J, Robinson M, Berger R, et al. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics 1998;52:173-85 (Pubitemid 28465664)
102. Sinkus ML, Lee MJ, Gault J, et al. A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia. Brain Res 2009;1291:1-11
103. Villiger Y, Szanto I, Jaconi S, et al. Expression of an alpha7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes. J Neuroimmunol 2002;126:86-98 (Pubitemid 34521734)
104. Benfante R, Antonini RA, De Pizzol M et al. Expression of the alpha7 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. J Neuroimmunol 2010;230(1-2):74-84
105. Steinlein OK, Mulley JC, Propping P et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-3
106. Steinlein OK, Bertrand D. Nicotinic receptor channelopathies and epilepsy. Pflugers Arch 2009;460(2):495-503
107. Steinlein OK. Animal models for autosomal dominant frontal lobe epilepsy: on the origin of seizures. Expert Rev Neurother 2010;10:1859-67
108. Steinlein OK, Hoda J-C, Bertrand S Bertrand D. Mutations in familial nocturnal frontal lobe epilepsy might be associated with distinct neurological phenotypes. Seizure 2012;21:118-23
109. Rempel N, Heyers S, Engels H, et al. The structures of the human neuronal nicotinic acetylcholine receptor beta2-and alpha3-subunit genes (CHRNB2 and CHRNA3). Hum Genet 1998;103:645-53 (Pubitemid 29020758)
110. Stefansson H, Rujescu D, Cichon S et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008;455:232-6
111. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008;455:237-41
112. Magnusson A, Stordal E, Brodtkorb E Steinlein O. Schizophrenia, psychotic illness and other psychiatric symptoms in families with autosomal dominant nocturnal frontal lobe epilepsy caused by different mutations. Psychiatr Genet 2003;13:91-5 (Pubitemid 36724537)
113. Bertrand D, Elmslie F, Hughes E, et al. The CHRNB2 mutation I312M is associated with epilepsy and distinct memory deficits. Neurobiol Dis 2005;20:799-804 (Pubitemid 41619355)
114. Freedman R, Hall M, Adler LE Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33
115. Tanibuchi Y, Wu J, Toyohara J, et al. Characterization of [(3)H]CHIBA-1001 binding to alpha7 nicotinic acetylcholine receptors in the brain from rat, monkey, and human. Brain Res 2010;1348:200-8
116. Toyohara J, Sakata M, Wu J, et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009;23:301-9
117. Toyohara J, Wu J, Hashimoto K. Recent development of radioligands for imaging alpha7 nicotinic acetylcholine receptors in the brain. Curr Top Med Chem 2010;10(15):1544-57
118. Liu Q, Huang Y, Xue F, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009;29:918-29
119. Khiroug SS, Harkness PC, Lamb PW et al. Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 2002;540:425
120. Murray TA, Bertrand D, Papke RL et al. alpha7beta2 nAChRs assemble and function, and are activated primarily via their alpha7-alpha7 Interfaces. Mol Pharmacol 2011;81:175-188
121. Wallace T, Porter R, Neveu E Bertrand D. Effects of RG3487 at the a7b2 nicotinic acetylcholine receptor expressed in Xenopus oocytes. Biochem Pharmacol 2011;82:1026
122. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63:630-8 (Pubitemid 43848294)
123. Tregellas JR, Tanabe J, Rojas DC, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2010;69(1):7-11
124. Freedman R, Olincy A, Buchanan RW et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-7
125. O'Donnell CJ, Rogers BN, Bronk BS et al. Discovery of 4-(5-Methyloxazolo [4,5-b]pyridin-2-yl)-1,4-diazabicyclo [3.2.2]nonane (CP-810,123), a novel alpha7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: Synthesis SAR development, and in vivo efficacy in cognition models. J Med Chem 2009;53:1222-237
126. Wishka DG, Walker DP, Yates KM et al. Discovery of N-[(3R)-1-azabicyclo [2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship. J Med Chem 2006;49:4425-36 (Pubitemid 44036685)
127. Walker DP, Wishka DG Piotrowski DW, et al. Design, synthesis structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem 2006;14:8219-48 (Pubitemid 44667561)
128. Hosford D, Dunbar G, Lieberman J Segreti A. The alpha7 neuronal nicotinic receptor (NNR) modulator TC-5619 had beneficial effects and was generally well tolerated in a phase 2 trial in cognitive dysfunction in schizophrenia (CDS) [Poster #48]. ACNP Annual Meeting; Waikoloa, Hawaii; 2011
129. Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 2010;9:27
130. Krause RM, Buisson B, Bertrand S, et al. Ivermectin: A positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283-94 (Pubitemid 28099739)
131. Timmermann DB, Grønlien JH Kohlhaas KL, et al. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 2007;323:294-307 (Pubitemid 47443280)
132. Bertrand D, Bertrand S, Cassar S, et al. Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Mol Pharmacol 2008;74:1407-16
133. Winterer G, Gallinat J, Brinkmeyer J et al. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study. Neuropharmacology 2012;64(1):197-204
134. Othman AA, Lenz RA, Zhang J, et al. Single- and multiple-dose pharmacokinetics, safety and tolerability of the selective {alpha}7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. J Clin Pharmacol 2010;51:512-526
135. Chailangkarn T, Acab A, Muotri AR. Modeling neurodevelopmental disorders using human neurons. Curr Opin Neurobiol 2012; [Epub ahead of print]
136. Davis RP, Casini S, van den Berg CW et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012;125:3079-91
137. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473:221-5
138. Giraudat J, Dennis M, Heidmann T et al. Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: Serine-262 of the delta subunit is labeled by [3H]chlorpromazine. Proc Natl Acad Sci USA 1986;83:2719-23 (Pubitemid 16026955)
139. Revah F, Galzi JL, Giraudat J, et al. The noncompetitive blocker [3H] chlorpromazine labels three amino acids of the acetylcholine receptor gamma subunit: implications for the alpha-helical organization of regions MII and for the structure of the ion channel. Proc Natl Acad Sci USA 1990;87:4675-9
140. Chiara DC, Hamouda AK, Ziebell MR et al. [(3)H]chlorpromazine photolabeling of the torpedo nicotinic acetylcholine receptor identifies two state-dependent binding sites in the ion channel. Biochemistry 2009;48:10066-77
141. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005;346:967-89 (Pubitemid 40215523)
142. Hilf RJC, Dutzler R. X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature 2008;452:375-9 (Pubitemid 351430790)
143. Bocquet N, Nury H, Baaden M, et al. X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 2009;457:111-14
144. Corringer P-J, Baaden M, Bocquet N et al. Atomic structure and dynamics of pentameric ligand-gated ion channels: new insight from bacterial homologues. J Physiol 2010;588:565-72
145. Singhal SK, Zhang L, Morales M Oz M. Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors. Neuropharmacology 2007;52:387-94 (Pubitemid 46137973)
146. Grinevich VP, Papke RL, Lippiello PM Bencherif M. Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology 2009;57:183-91
147. Ashoor A, Lorke D, Nurulain SM, et al. Effects of phenothiazine-class antipsychotics on the function of alpha7-nicotinic acetylcholine receptors. Eur J Pharmacol 2011;673:25-32
148. Addy N, Levin ED. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 2002;27:534-41
149. Simosky JK, Freedman R, Stevens KE. Olanzapine improves deficient sensory inhibition in DBA/2 mice. Brain Res 2008;1233:129-36
150. Simosky JK, Stevens KE, Adler LE Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 2003;165:386-96 (Pubitemid 36223080)
151. Stip E. Cognition, schizophrenia and the effect of antipsychotics. Encephale 2006;32:341-350 (Pubitemid 43941530)
152. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010;4:56-73
153. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475:91-5
154. Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4 (Pubitemid 30109248)
155. Kapur S, Seeman P. Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. Biol Psychiatry 2001;49:954-7 (Pubitemid 32493818)
156. Krystal JH, D'Souza DC. Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D(2) receptor". Biol Psychiatry 2001;50:555-6
157. Coates KM, Flood P. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol 2001;134:871-9
158. Yamakura T, Chavez-Noriega LE Harris RA. Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 2000;92:1144-53 (Pubitemid 30180992)
159. Ho KK, Flood P. Single amino acid residue in the extracellular portion of transmembrane segment 2 in the nicotinic alpha7 acetylcholine receptor modulates sensitivity to ketamine. Anesthesiology 2004;100:657-62 (Pubitemid 38268886)
160. Jentsch JD, Elsworth JD, Redmond DE Roth RH. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J Neurosci 1997;17:1769-75 (Pubitemid 27089821)
161. Tsukada H, Nishiyama S, Fukumoto D et al. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005;30:1861-9 (Pubitemid 41486411)
162. Buccafusco JJ, Terry AV. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 2009;78:852-62
163. Cannon CE, Puri V, Vivian JA, et al. The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology 2012;64(1):191-6
164. Terry AV, Gearhart DA, Mahadik SP et al. Chronic exposure to typical or atypical antipsychotics in rodents: Temporal effects on central alpha7 nicotinic acetylcholine receptors. Neuroscience 2005;136:519-29 (Pubitemid 41607900)
165. Perry DC, Davila-Garcia MI Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 1999;289:1545-52 (Pubitemid 29246689)
166. Molinari EJ, Delbono O, Messi ML et al. Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands. Eur J Pharmacol 1998;347:131-9 (Pubitemid 28238097)
167. Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J Neurosci 2001;21:1819-29 (Pubitemid 32221365)
168. Cho C-H, Song W, Leitzell K, et al. Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J Neurosci 2005;25:3712-23
169. Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009;78:756-65
170. Govind AP, Walsh H, Green WN. Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms. J Neurosci 2012;32:2227-38
171. AhnAllen CG. The role of the alpha7 nicotinic receptor in cognitive processing of persons with schizophrenia. Curr Opin Psychiatry 2012;25:103-8